LEADER 04589nam 2201261z- 450 001 9910580213503321 005 20220706 035 $a(CKB)5690000000011953 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87433 035 $a(oapen)doab87433 035 $a(EXLCZ)995690000000011953 100 $a20202207d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMicroRNA and Cancer 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (298 p.) 311 08$a3-0365-4416-X 311 08$a3-0365-4415-1 330 $aMicroRNAs (miRs) are small noncoding RNAs that function as post-transcriptional regulators of gene expression and have important roles in almost all biological pathways. Deregulated miR expression has been detected in numerous cancers, where miRs act as both oncogene and tumor suppressors. Due to their important roles in tumorigenesis, miRs have been investigated as prognostic and diagnostic biomarkers and as useful targets for therapeutic intervention. From a therapeutic point of view, two modalities can serve to rectify gene networks in cancer cells. For oncomiRs, a rational means is downregulation through antagomirs. Moreover, observations of the pathological reductions in tumor-suppressive miRs have inspired the concept of "miR replacement therapy" to enhance the amount of these miRs, thereby restoring them to normal levels. However, the clinical applicability of miR-based therapies is severely limited by the lack of effective delivery systems. Therefore, to understand the role of this new class of regulators, we need to identify the mRNA targets regulated by individual miRs as well as to develop specific, efficient, and safe delivery systems for therapeutic miRs. 606 $aBiology, life sciences$2bicssc 606 $aResearch & information: general$2bicssc 610 $a2'-O-methylation 610 $aadipokines 610 $aB-CLL 610 $abioinformatics analysis 610 $abiomarker 610 $ablood biomarker 610 $abrain tumour 610 $abreast cancer 610 $aBreast cancer 610 $acancer stem cell 610 $acancer stem cells 610 $accRCC 610 $acirculating biomarkers 610 $acirculating microRNA 610 $acolon cancer 610 $aCyclooxygenase-2 (COX-2) 610 $adeformability 610 $adiagnosis 610 $aendometrial cancer 610 $aestrogens 610 $aexosome 610 $ahead and neck squamous cell carcinoma 610 $ahepatocellular carcinoma 610 $ahyperinsulinemia 610 $aHypoxia inducible factor 1-alpha (HIF-1?) 610 $aimmune checkpoint inhibitors 610 $aimmunotherapy 610 $ainsulin 610 $ainsulin resistance 610 $ainsulin signaling 610 $ainsulin-like growth factors 610 $amalignant melanoma 610 $amedulloblastoma 610 $ameta-analysis 610 $ametastasis 610 $ametastatic melanoma 610 $amethylation 610 $amicroRNA 610 $aMicroRNA (miRNA) 610 $amicroRNAs 610 $aMigration 610 $amiR-584-5p 610 $amiR526b 610 $amiR655 610 $amiRNA 610 $amiRNA-transcription factor network 610 $amiRNAs 610 $an/a 610 $anon-small cell lung cancer 610 $anormal B-cell development 610 $aovarian cancer 610 $aOxidative stress 610 $aPARP 610 $aPI3K/Akt 610 $aplasma 610 $aprediction 610 $aprognosis 610 $aprognostic factor 610 $aprogression 610 $aProstaglandin E2 receptor 4 (EP4) 610 $apseudouridylation 610 $aRCC 610 $aregulation 610 $arenal cancer 610 $areplication stress 610 $aserum LDH 610 $asmoking 610 $asnoRNA 610 $astem cells 610 $astemness 610 $asubgroups 610 $asurvival 610 $atargeted therapy 610 $atherapy 610 $aYKT6 615 7$aBiology, life sciences 615 7$aResearch & information: general 700 $aTucci$b Paola$4edt$01304525 702 $aTucci$b Paola$4oth 906 $aBOOK 912 $a9910580213503321 996 $aMicroRNA and Cancer$93027525 997 $aUNINA